- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02710747
The Pharmacogenetics of Optimal Warfarin Therapy in Chinese Patients After Heart Valve Replacement. (POWAT)
March 11, 2016 updated by: Guangdong Provincial People's Hospital
To value the accuracy of the dosing algorithm published by the International Warfarin Pharmacogenetics Consortium in Chinese patients after heart valve replacement.
To value the accuracy of warfarin pharmacogenomics algorithm by the algorithm calculated dose and actual dose in the Chinese patients.
Study Overview
Status
Unknown
Intervention / Treatment
Detailed Description
The dosing algorithm published by the International Warfarin Pharmacogenetics Consortium hadn't been verifying by a standard randomized prospective study in Chinese patients after heart valve replacement.
And, warfarin will affect people's coagulation, so that probably increase the drainage.
We'll analyse the interaction of patients' PT-INR or drainge and oral warfarin dosing.
Study Type
Interventional
Enrollment (Anticipated)
500
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510080
- Recruiting
- Guangdong General Hospital
-
Contact:
- Chen Yongbin, Master
- Phone Number: +8618688859129
- Email: chenyb1020@hotmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:atrial fibrillation
- atrial fibrillation
- heart valve replacement
- VTE
Exclusion Criteria:
- severe liver or kidney diseases
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Genetic Group
Dose (mg/week) = [5.6044
- 0.02614 × Age [in years] + 0.0087 × Height [cm] + 0.0128 × Weight [kg] - 0.8677 × VKORC1 A/G -1.6974 × VKORC1 A/A - 0.5211 × CYP2C9 *1/*2 - 0.9357 × CYP2C9 *1/*3 - 1.0616 × CYP2C9 *2/*2 - 1.9206 × CYP2C9*2/*3 - 2.3312 × CYP2C9 *3/*3 - 0.1092 × Asian race - 0.5503 × amiodarone ]2
|
|
|
No Intervention: Control Group
Dose for the first three days after operation will be 4.5mg/d.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The perccentage of time that the INR was in the therapeutic range
Time Frame: 3 months
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
all drainage fluid of every patient
Time Frame: 1 week after operation
|
1 week after operation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2015
Primary Completion (Anticipated)
June 1, 2016
Study Completion (Anticipated)
July 1, 2016
Study Registration Dates
First Submitted
February 25, 2016
First Submitted That Met QC Criteria
March 11, 2016
First Posted (Estimate)
March 17, 2016
Study Record Updates
Last Update Posted (Estimate)
March 17, 2016
Last Update Submitted That Met QC Criteria
March 11, 2016
Last Verified
December 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GDREC2014265H
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.